NEWS: JANUARY 2005

-01/07/2004-

FDA approves American Pharmaceutical Partners' drug Abraxane for the treatment of metastatic breast cancer. To read article click here.

Albany Molecular Research Inc. and Alcon Inc. sign two-year discovery collaboration for eye treatments. To read article click here.

Roche inlicenes Elan Corporation's proprietary NanoCrystal® technology. To read article click here.

-01/06/2004-

FDA grants Panacos Pharmaceuticals Inc.'s PA-457 fast-track status for HIV. To read article click here.

Merck & Co. and Vertex Pharmaceuticals Inc. initiate Phase I clinical trials of small-molecule Aurora kinase inhibtor VX-680 for solid tumor cancer. To read article click here.

ViroPharma Inc. files IND for compound HCV-796 for hepatitis C (HCV). To read article click here.

Savient Pharmaceuticals Inc. files NDA for Soltamox® for hormonally sensitive breast cancer. To read article click here.

Sirna Therapeutics launches program to treat diabetes with RNAi technology. To read article click here.

-01/05/2004-

Sankyo Co. Ltd. and Metabasis Therapeutics Inc. initiate Phase IIb clinical trials of CS-917 for type 2 diabetes. To read article click here.

FDA grants Immunomedics Inc.'s epratuzumab fast-track status for lupus. To read article click here.

Keryx Biopharmaceuticals Inc. will start Phase III clinical trial of KRX-101 for its diabetic nephropathy. To read article click here.

Sangamo BioSciences Inc. and Pfizer Inc. for alliance to produce enhanced proteins. To read article click here.

Manhattan Pharmaceuticals Inc. to merge with Tarpan Therapeutics. To read article click here.

Galapagos BioSciences Inc. inks multi-year target identification collaboration with GlaxoSmithKline for respiratory and inflammatory diseases. To read article click here.

Tripos Inc. acquires Optive Research Inc. To read article click here.

-01/04/2004-

AstraZeneca Plc pulls marketing application for lung cancer pill Iressa in Europe. To read article click here.

Telik Inc. will present an update at the 23rd Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 10, 2005 at 3:00 p.m. To read article click here.

NeoPharm Inc. licenses to Nippon Kayaku Co. development rights to lead brain tumor drug candidate IL13-PE38QQR. To read article click here.

Targeted Genetics Corp. and Celladon Corp. form collaboration to develop gene therapies. To read article click here.

-01/05/2004-

Theravance Inc. initiates Phase I clinical trials of TD-2749 for gastrointestinal motility dysfunction. To read article click here.

Adolor Corp. to co-promote GlaxoSmithKline PLC's anti-blood clot drug Arixtra. To read article click here.

BioSource International Inc. sells custom antibody and peptide business. To read article click here.

MGI PHARMA INC. and SuperGen Inc. file NDA for Dacogen(TM) for injection. To read article click here.

SuperGen Inc. withdraw NDA for Orathecin capsules. To read article click here.